Lexicon Q3 10-Q: $183.2M Cash, Wider $46.8M Nine-Month Loss, Hercules Debt in Place
LXRX sits 47% above its 52-week low of $1.1.
Summary
Lexicon's Q3 10-Q shows $183.2 million in cash and investments against a $46.8 million nine-month net loss, with the new Hercules term loan carrying a minimum cash covenant starting June 1, 2027.
Key Events · Earnings and Guidance · LXRX
-
Q3 Revenue Falls on Smaller Milestone
Total revenue was $11.3 million versus $14.2 million a year ago; $10.0 million came from the Novo Nordisk license milestone and only $1.2 million from INPEFA product sales.
-
Cash Position Rises to $183.2M
Cash, cash equivalents and short-term investments reached $183.2 million at September 30, 2026, up from $125.2 million at December 31, 2025, after $96.2 million of net February equity proceeds.
-
Nine-Month Net Loss Widens
Net loss was $46.8 million, or $0.11 per share, versus $34.8 million, or $0.10 per share, a year earlier, including a $4.3 million loss on early extinguishment of the Oxford debt.
-
Hercules Loan Covenant Starts June 2027
The $100 million Hercules facility had $55 million funded at a 10.10% rate; a minimum cash covenant begins June 1, 2027, extendable to January 1, 2028 on milestone achievement and waivable at specified market caps.
Analysis · LXRX · Life Sciences
The headline numbers were already out this morning, but the 10-Q is where the balance sheet lives: $183.2 million of cash and short-term investments at September 30 versus $125.2 million at year-end, after a February raise that netted $96.2 million and a May refinancing that swapped the Oxford loans for a $100 million Hercules facility. That cash covers the stated 12-month runway, but the nine-month net loss widened to $46.8 million from $34.8 million, and the Hercules minimum cash covenant begins June 1, 2027 — the date that matters if the SONATA-HCM readout or a ZYNQUISTA resubmission slips. Revenue of $11.3 million was almost entirely the $10 million Novo Nordisk milestone, so product sales of $1.2 million remain the weak spot.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LXRX was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $716.4M. The 52-week trading range was $1.10 to $2.68. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.